Cognition Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Cognition Therapeutics

03/08/2026 12:04

Cognition Therapeutics Inc CGTX.OQ CGTX.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Cognition Therapeutics Inc is for a loss of 6 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.00, about 237.2% above its last closing price of $0.89
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.07
-0.07
-0.05
Beat
25.9
Dec. 31 2026
-0.08
-0.05
Beat
42.4
Sep. 30 2025
-0.14
-0.10
-0.06
Beat
40​
Jun. 30 2025
-0.10
-0.11
-0.11
Met
-3.1
​​Mar. 31 2025
-0.11
-0.11
-0.14
Missed
-27
Dec. 31 2024
-0.15
-0.14
-0.17
Missed
-19.7​
Sep. 30 2024
-0.18
-0.22
-0.25
Missed
-11.1
Jun. 30 2024
-0.22
-0.24
-0.18
Beat
23.7
This summary was machine generated August 3 at 11:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)